US Pharma MarketingCSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion. Additionally, the Australian company is writing off $5 billion in assets.
Source: FiercePharma